Literature DB >> 10444274

Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis.

H Ihn1, K Yamane, N Yazawa, M Kubo, M Fujimoto, S Sato, K Kikuchi, K Tamaki.   

Abstract

Systemic sclerosis (SSc) is a generalized connective tissue disease which is characterized by the presence of several autoantibodies. To determine the prevalence and antigen specificity of anti-U1RNP antibodies (anti-U1RNP) in patients with SSc, serum samples from 223 patients with SSc, 117 patients with systemic lupus erythematosus (SLE), 18 patients with mixed connective tissue disease (MCTD) and 40 healthy control subjects were examined by indirect immunofluorescent analysis (IIF), double immunodiffusion, and immunoblotting using nuclear extract of HeLa cells. Eighteen of the 223 (8%) serum samples from patients with SSc were shown to be positive for anti-U1RNP. The frequency of anti-U1RNP positivity in limited cutaneous SSc (14%) was significantly higher than that in those with diffuse cutaneous SSc (3%). Anti-Sm antibodies were detected in patients with SLE positive for anti-U1RNP, but not in those with SSc positive for anti-U1RNP or those with MCTD. Immunoblotting demonstrated that anti-70-kD antibodies were detected more often in patients with SSc positive for anti-U1RNP and in those with MCTD than in those with SLE. Furthermore, anti-U1RNP was closely correlated with pulmonary fibrosis and joint involvement in patients with SSc. These results suggest that anti-70-kD antibodies are useful in the classification of patients with anti-U1RNP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10444274      PMCID: PMC1905346          DOI: 10.1046/j.1365-2249.1999.00961.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

Review 1.  Clinical and serologic characteristics of patients with overlap syndrome: is mixed connective tissue disease a distinct clinical entity?

Authors:  M A Lázaro; J A Maldonado Cocco; L J Catoggio; S M Babini; O D Messina; O García Morteo
Journal:  Medicine (Baltimore)       Date:  1989-01       Impact factor: 1.889

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.

Authors:  C C Bunn; C P Denton; X Shi-Wen; C Knight; C M Black
Journal:  Br J Rheumatol       Date:  1998-01

4.  Sp3 is a transcriptional activator of the human alpha2(I) collagen gene.

Authors:  H Ihn; M Trojanowska
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

5.  Oncostatin M stimulates transcription of the human alpha2(I) collagen gene via the Sp1/Sp3-binding site.

Authors:  H Ihn; E C LeRoy; M Trojanowska
Journal:  J Biol Chem       Date:  1997-09-26       Impact factor: 5.157

6.  Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis.

Authors:  M Fujimoto; M Shimozuma; N Yazawa; M Kubo; H Ihn; S Sato; T Tamaki; K Kikuchi; K Tamaki
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

Review 7.  The role of small nuclear ribonucleoprotein particles in pre-mRNA splicing.

Authors:  T Maniatis; R Reed
Journal:  Nature       Date:  1987 Feb 19-25       Impact factor: 49.962

8.  Splicing of messenger RNA precursors.

Authors:  P A Sharp
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

9.  Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.

Authors:  E S Weiner; W C Earnshaw; J L Senécal; B Bordwell; P Johnson; N F Rothfield
Journal:  Arthritis Rheum       Date:  1988-03

10.  Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis.

Authors:  H Ihn; S Sato; M Fujimoto; K Kikuchi; A Igarashi; Y Soma; K Tamaki; K Takehara
Journal:  Clin Exp Immunol       Date:  1996-09       Impact factor: 4.330

View more
  8 in total

1.  Clinical features of scleroderma patients with contracture of phalanges.

Authors:  Ryuichi Ashida; Hironobu Ihn; Yoshihiro Mimura; Masatoshi Jinnin; Yoshihide Asano; Masahide Kubo; Kunihiko Tamaki
Journal:  Clin Rheumatol       Date:  2006-12-15       Impact factor: 2.980

Review 2.  Autoantibodies as predictive tools in systemic sclerosis.

Authors:  Svetlana I Nihtyanova; Christopher P Denton
Journal:  Nat Rev Rheumatol       Date:  2010-02       Impact factor: 20.543

3.  Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients.

Authors:  Hadi Poormoghim; Alireza Salek Moghadam; Maziar Moradi-Lakeh; Mehrzad Jafarzadeh; Behnam Asadifar; Mohsen Ghelman; Elham Andalib
Journal:  Rheumatol Int       Date:  2013-01-24       Impact factor: 2.631

Review 4.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

Review 5.  Personalized medicine in rheumatology: the paradigm of serum autoantibodies.

Authors:  Silvia Sirotti; Elena Generali; Angela Ceribelli; Natasa Isailovic; Maria De Santis; Carlo Selmi
Journal:  Auto Immun Highlights       Date:  2017-07-12

Review 6.  Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?

Authors:  Kevin Didier; Loïs Bolko; Delphine Giusti; Segolene Toquet; Ailsa Robbins; Frank Antonicelli; Amelie Servettaz
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

7.  Interkit Reproducibility of the Indirect Immunofluorescence Assay on HEp-2 Cells Depends on the Immunofluorescence Reactivity Intensity and Pattern.

Authors:  Mônica Jesus Silva; Alessandra Dellavance; Danielle Cristiane Baldo; Silvia Helena Rodrigues; Marcelle Grecco; Monica Simon Prado; Renan Agustinelli; Luís Eduardo Coelho Andrade
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

Review 8.  Predicting the Progression of Very Early Systemic Sclerosis: Current Insights.

Authors:  Chiara Bellocchi; Augustine Chung; Elizabeth R Volkmann
Journal:  Open Access Rheumatol       Date:  2022-09-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.